Eli Lilly Net Worth
Eli Lilly Net Worth Breakdown | LLY |
Eli Lilly Net Worth Analysis
Eli Lilly's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Eli Lilly's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Eli Lilly's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Eli Lilly's net worth analysis. One common approach is to calculate Eli Lilly's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Eli Lilly's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Eli Lilly's net worth. This approach calculates the present value of Eli Lilly's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Eli Lilly's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Eli Lilly's net worth. This involves comparing Eli Lilly's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Eli Lilly's net worth relative to its peers.
Enterprise Value |
|
To determine if Eli Lilly is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eli Lilly's net worth research are outlined below:
Eli Lilly has a poor financial position based on the latest SEC disclosures | |
Over 84.0% of the company shares are owned by institutional investors | |
On 10th of March 2025 Eli Lilly paid $ 1.5 per share dividend to its current shareholders | |
Latest headline from seekingalpha.com: Eli Lilly snaps six days of losses |
Eli Lilly uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eli Lilly and. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eli Lilly's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of February 2024 Upcoming Quarterly Report | View | |
25th of April 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
6th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Eli Lilly Target Price Consensus
Eli target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Eli Lilly's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
28 | Strong Buy |
Most Eli analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Eli stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Eli Lilly, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEli Lilly Target Price Projection
Eli Lilly's current and average target prices are 824.76 and 984.05, respectively. The current price of Eli Lilly is the price at which Eli Lilly and is currently trading. On the other hand, Eli Lilly's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Eli Lilly Market Quote on 18th of March 2025
Target Price
Analyst Consensus On Eli Lilly Target Price
Know Eli Lilly's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eli Lilly is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eli Lilly and backward and forwards among themselves. Eli Lilly's institutional investor refers to the entity that pools money to purchase Eli Lilly's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 14.4 M | State Farm Mutual Automobile Ins Co | 2024-12-31 | 12.6 M | Wellington Management Company Llp | 2024-12-31 | 12.6 M | International Assets Investment Management, Llc | 2024-09-30 | 12.5 M | Norges Bank | 2024-12-31 | 10.9 M | Capital Research Global Investors | 2024-12-31 | 10.8 M | Bank Of America Corp | 2024-12-31 | 10 M | Northern Trust Corp | 2024-12-31 | 9.4 M | Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 8.7 M | Lilly Endowment Inc | 2024-12-31 | 96.9 M | Vanguard Group Inc | 2024-12-31 | 74.2 M |
Follow Eli Lilly's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 730.64 B.Market Cap |
|
Project Eli Lilly's profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.16 | 0.14 | |
Return On Capital Employed | 0.26 | 0.25 | |
Return On Assets | 0.13 | 0.12 | |
Return On Equity | 0.74 | 0.78 |
When accessing Eli Lilly's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Eli Lilly's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eli Lilly's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Eli Lilly's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eli Lilly and. Check Eli Lilly's Beneish M Score to see the likelihood of Eli Lilly's management manipulating its earnings.
Evaluate Eli Lilly's management efficiency
Eli Lilly has Return on Asset of 0.1533 % which means that on every $100 spent on assets, it made $0.1533 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.8426 %, implying that it generated $0.8426 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.78 in 2025, whereas Return On Tangible Assets are likely to drop 0.14 in 2025. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 48.3 B in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 3 B in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 15.90 | 16.70 | |
Tangible Book Value Per Share | 2.60 | 4.64 | |
Enterprise Value Over EBITDA | 47.50 | 36.98 | |
Price Book Value Ratio | 48.38 | 50.80 | |
Enterprise Value Multiple | 47.50 | 36.98 | |
Price Fair Value | 48.38 | 50.80 | |
Enterprise Value | 492 B | 516.6 B |
The decision-making processes within Eli Lilly are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 16.8921 | Revenue | Quarterly Revenue Growth 0.447 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eli Lilly insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eli Lilly's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eli Lilly insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eli Lilly Corporate Filings
F4 | 13th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
7th of March 2025 Other Reports | ViewVerify | |
10K | 19th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 12th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Eli Lilly Earnings Estimation Breakdown
The calculation of Eli Lilly's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Eli Lilly is estimated to be 4.6911 with the future projection ranging from a low of 4.2 to a high of 5.36. Please be aware that this consensus of annual earnings estimates for Eli Lilly and is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
4.20 Lowest | Expected EPS | 5.36 Highest |
Eli Lilly Earnings Projection Consensus
Suppose the current estimates of Eli Lilly's value are higher than the current market price of the Eli Lilly stock. In this case, investors may conclude that Eli Lilly is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Eli Lilly's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
28 | 82.32% | 5.32 | 4.6911 | 11.71 |
Eli Lilly Earnings History
Earnings estimate consensus by Eli Lilly analysts from Wall Street is used by the market to judge Eli Lilly's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Eli Lilly's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Eli Lilly Quarterly Gross Profit |
|
Eli Lilly Earnings per Share Projection vs Actual
Actual Earning per Share of Eli Lilly refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Eli Lilly and predict the company's earnings will be in the future. The higher the earnings per share of Eli Lilly, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Eli Lilly Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Eli Lilly, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Eli Lilly should always be considered in relation to other companies to make a more educated investment decision.Eli Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Eli Lilly's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2025-02-06 | 2024-12-31 | 5.0668 | 5.32 | 0.2532 | 4 | ||
2024-10-30 | 2024-09-30 | 1.47 | 1.18 | -0.29 | 19 | ||
2024-08-08 | 2024-06-30 | 2.6 | 3.92 | 1.32 | 50 | ||
2024-04-30 | 2024-03-31 | 2.46 | 2.58 | 0.12 | 4 | ||
2024-02-06 | 2023-12-31 | 2.22 | 2.49 | 0.27 | 12 | ||
2023-11-02 | 2023-09-30 | -0.13 | 0.1 | 0.23 | 176 | ||
2023-08-08 | 2023-06-30 | 1.98 | 2.11 | 0.13 | 6 | ||
2023-04-27 | 2023-03-31 | 1.73 | 1.62 | -0.11 | 6 | ||
2023-02-02 | 2022-12-31 | 1.78 | 2.09 | 0.31 | 17 | ||
2022-11-01 | 2022-09-30 | 1.92 | 1.98 | 0.06 | 3 | ||
2022-08-04 | 2022-06-30 | 1.69 | 1.25 | -0.44 | 26 | ||
2022-04-28 | 2022-03-31 | 2.32 | 2.77 | 0.45 | 19 | ||
2022-02-03 | 2021-12-31 | 2.46 | 2.49 | 0.03 | 1 | ||
2021-10-26 | 2021-09-30 | 1.98 | 1.94 | -0.04 | 2 | ||
2021-08-03 | 2021-06-30 | 1.89 | 1.87 | -0.02 | 1 | ||
2021-04-27 | 2021-03-31 | 2.13 | 1.87 | -0.26 | 12 | ||
2021-01-29 | 2020-12-31 | 2.35 | 2.75 | 0.4 | 17 | ||
2020-10-27 | 2020-09-30 | 1.71 | 1.54 | -0.17 | 9 | ||
2020-07-30 | 2020-06-30 | 1.56 | 1.89 | 0.33 | 21 | ||
2020-04-23 | 2020-03-31 | 1.48 | 1.75 | 0.27 | 18 | ||
2020-01-30 | 2019-12-31 | 1.52 | 1.73 | 0.21 | 13 | ||
2019-10-23 | 2019-09-30 | 1.41 | 1.48 | 0.07 | 4 | ||
2019-07-30 | 2019-06-30 | 1.45 | 1.5 | 0.05 | 3 | ||
2019-04-30 | 2019-03-31 | 1.31 | 1.33 | 0.02 | 1 | ||
2019-02-06 | 2018-12-31 | 1.34 | 1.33 | -0.01 | 0 | ||
2018-11-06 | 2018-09-30 | 1.35 | 1.39 | 0.04 | 2 | ||
2018-07-24 | 2018-06-30 | 1.3 | 1.5 | 0.2 | 15 | ||
2018-04-24 | 2018-03-31 | 1.13 | 1.34 | 0.21 | 18 | ||
2018-01-31 | 2017-12-31 | 1.07 | 1.14 | 0.07 | 6 | ||
2017-10-24 | 2017-09-30 | 1.03 | 1.05 | 0.02 | 1 | ||
2017-07-25 | 2017-06-30 | 1.05 | 1.11 | 0.06 | 5 | ||
2017-04-25 | 2017-03-31 | 0.96 | 0.98 | 0.02 | 2 | ||
2017-01-31 | 2016-12-31 | 0.98 | 0.95 | -0.03 | 3 | ||
2016-10-25 | 2016-09-30 | 0.96 | 0.88 | -0.08 | 8 | ||
2016-07-26 | 2016-06-30 | 0.86 | 0.86 | 0.0 | 0 | ||
2016-04-26 | 2016-03-31 | 0.85 | 0.83 | -0.02 | 2 | ||
2016-01-28 | 2015-12-31 | 0.78 | 0.78 | 0.0 | 0 | ||
2015-10-22 | 2015-09-30 | 0.76 | 0.89 | 0.13 | 17 | ||
2015-07-23 | 2015-06-30 | 0.74 | 0.9 | 0.16 | 21 | ||
2015-04-23 | 2015-03-31 | 0.77 | 0.87 | 0.1 | 12 | ||
2015-01-30 | 2014-12-31 | 0.73 | 0.75 | 0.02 | 2 | ||
2014-10-23 | 2014-09-30 | 0.67 | 0.66 | -0.01 | 1 | ||
2014-07-24 | 2014-06-30 | 0.65 | 0.68 | 0.03 | 4 | ||
2014-04-24 | 2014-03-31 | 0.7 | 0.7 | 0.0 | 0 | ||
2014-01-30 | 2013-12-31 | 0.74 | 0.74 | 0.0 | 0 | ||
2013-10-23 | 2013-09-30 | 1.04 | 1.11 | 0.07 | 6 | ||
2013-07-24 | 2013-06-30 | 1 | 1.16 | 0.16 | 16 | ||
2013-04-24 | 2013-03-31 | 1.05 | 1.14 | 0.09 | 8 | ||
2013-01-29 | 2012-12-31 | 0.78 | 0.85 | 0.07 | 8 | ||
2012-10-24 | 2012-09-30 | 0.83 | 0.79 | -0.04 | 4 | ||
2012-07-25 | 2012-06-30 | 0.77 | 0.83 | 0.06 | 7 | ||
2012-04-25 | 2012-03-31 | 0.78 | 0.92 | 0.14 | 17 | ||
2012-01-31 | 2011-12-31 | 0.81 | 0.87 | 0.06 | 7 | ||
2011-10-20 | 2011-09-30 | 1.13 | 1.13 | 0.0 | 0 | ||
2011-07-21 | 2011-06-30 | 1.18 | 1.18 | 0.0 | 0 | ||
2011-04-18 | 2011-03-31 | 1.17 | 1.24 | 0.07 | 5 | ||
2011-01-27 | 2010-12-31 | 1.1 | 1.11 | 0.01 | 0 | ||
2010-10-21 | 2010-09-30 | 1.15 | 1.21 | 0.06 | 5 | ||
2010-07-22 | 2010-06-30 | 1.1 | 1.24 | 0.14 | 12 | ||
2010-04-19 | 2010-03-31 | 1.1 | 1.18 | 0.08 | 7 | ||
2010-01-28 | 2009-12-31 | 0.92 | 0.91 | -0.01 | 1 | ||
2009-10-21 | 2009-09-30 | 1.02 | 1.2 | 0.18 | 17 | ||
2009-07-22 | 2009-06-30 | 1.02 | 1.12 | 0.1 | 9 | ||
2009-04-20 | 2009-03-31 | 0.99 | 1.2 | 0.21 | 21 | ||
2009-01-29 | 2008-12-31 | 1.05 | 1.07 | 0.02 | 1 | ||
2008-10-23 | 2008-09-30 | 1.02 | 1.04 | 0.02 | 1 | ||
2008-07-24 | 2008-06-30 | 1 | 0.99 | -0.01 | 1 | ||
2008-04-21 | 2008-03-31 | 0.96 | 0.92 | -0.04 | 4 | ||
2008-01-29 | 2007-12-31 | 0.89 | 0.9 | 0.01 | 1 | ||
2007-10-18 | 2007-09-30 | 0.87 | 0.91 | 0.04 | 4 | ||
2007-07-24 | 2007-06-30 | 0.82 | 0.9 | 0.08 | 9 | ||
2007-04-16 | 2007-03-31 | 0.79 | 0.84 | 0.05 | 6 | ||
2007-01-31 | 2006-12-31 | 0.82 | 0.85 | 0.03 | 3 | ||
2006-10-19 | 2006-09-30 | 0.79 | 0.8 | 0.01 | 1 | ||
2006-07-21 | 2006-06-30 | 0.75 | 0.76 | 0.01 | 1 | ||
2006-04-20 | 2006-03-31 | 0.75 | 0.77 | 0.02 | 2 | ||
2006-01-26 | 2005-12-31 | 0.78 | 0.8 | 0.02 | 2 | ||
2005-10-20 | 2005-09-30 | 0.71 | 0.73 | 0.02 | 2 | ||
2005-07-21 | 2005-06-30 | 0.67 | 0.67 | 0.0 | 0 | ||
2005-04-18 | 2005-03-31 | 0.66 | 0.68 | 0.02 | 3 | ||
2005-01-26 | 2004-12-31 | 0.74 | 0.75 | 0.01 | 1 | ||
2004-10-21 | 2004-09-30 | 0.68 | 0.69 | 0.01 | 1 | ||
2004-07-22 | 2004-06-30 | 0.68 | 0.68 | 0.0 | 0 | ||
2004-04-19 | 2004-03-31 | 0.66 | 0.7 | 0.04 | 6 | ||
2004-01-29 | 2003-12-31 | 0.67 | 0.67 | 0.0 | 0 | ||
2003-10-22 | 2003-09-30 | 0.66 | 0.66 | 0.0 | 0 | ||
2003-07-24 | 2003-06-30 | 0.6 | 0.64 | 0.04 | 6 | ||
2003-04-22 | 2003-03-31 | 0.58 | 0.61 | 0.03 | 5 | ||
2003-01-23 | 2002-12-31 | 0.68 | 0.68 | 0.0 | 0 | ||
2002-10-23 | 2002-09-30 | 0.68 | 0.68 | 0.0 | 0 | ||
2002-07-18 | 2002-06-30 | 0.61 | 0.61 | 0.0 | 0 | ||
2002-04-15 | 2002-03-31 | 0.58 | 0.58 | 0.0 | 0 | ||
2002-01-24 | 2001-12-31 | 0.6 | 0.6 | 0.0 | 0 | ||
2001-10-18 | 2001-09-30 | 0.66 | 0.66 | 0.0 | 0 | ||
2001-07-19 | 2001-06-30 | 0.74 | 0.76 | 0.02 | 2 | ||
2001-04-16 | 2001-03-31 | 0.73 | 0.74 | 0.01 | 1 | ||
2001-01-25 | 2000-12-31 | 0.7 | 0.7 | 0.0 | 0 | ||
2000-10-19 | 2000-09-30 | 0.71 | 0.71 | 0.0 | 0 | ||
2000-07-20 | 2000-06-30 | 0.6 | 0.61 | 0.01 | 1 | ||
2000-04-17 | 2000-03-31 | 0.61 | 0.63 | 0.02 | 3 | ||
2000-01-27 | 1999-12-31 | 0.61 | 0.61 | 0.0 | 0 | ||
1999-10-20 | 1999-09-30 | 0.62 | 0.62 | 0.0 | 0 | ||
1999-07-21 | 1999-06-30 | 0.51 | 0.52 | 0.01 | 1 | ||
1999-04-19 | 1999-03-31 | 0.53 | 0.53 | 0.0 | 0 | ||
1999-01-28 | 1998-12-31 | 0.51 | 0.5 | -0.01 | 1 | ||
1998-10-21 | 1998-09-30 | 0.51 | 0.53 | 0.02 | 3 | ||
1998-07-22 | 1998-06-30 | 0.43 | 0.45 | 0.02 | 4 | ||
1998-04-20 | 1998-03-31 | 0.46 | 0.47 | 0.01 | 2 | ||
1998-01-29 | 1997-12-31 | 0.42 | 0.41 | -0.01 | 2 | ||
1997-10-20 | 1997-09-30 | 0.4 | 0.41 | 0.01 | 2 | ||
1997-07-23 | 1997-06-30 | 0.38 | 0.38 | 0.0 | 0 | ||
1997-04-21 | 1997-03-31 | 0.4 | 0.41 | 0.01 | 2 | ||
1997-01-27 | 1996-12-31 | 0.34 | 0.34 | 0.0 | 0 | ||
1996-10-22 | 1996-09-30 | 0.32 | 0.38 | 0.06 | 18 | ||
1996-07-16 | 1996-06-30 | 0.32 | 0.32 | 0.0 | 0 | ||
1996-04-15 | 1996-03-31 | 0.36 | 0.36 | 0.0 | 0 |
Eli Lilly Corporate Directors
Kathi Seifert | Independent Director | Profile | |
Jamere Jackson | Independent Director | Profile | |
Juan Luciano | Lead Independent Director | Profile | |
Gabrielle Sulzberger | Independent Director | Profile |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.